Back to Search
Start Over
Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen
- Source :
- Vaccine. 25:5343-5347
- Publication Year :
- 2007
- Publisher :
- Elsevier BV, 2007.
-
Abstract
- CpG oligodeoxynucleotides are potent immunostimulants. In this study, CPG 7909 was formulated with the recombinant Plasmodium falciparum protein AMA1-C1 adsorbed to Alhydrogel (aluminum hydroxide) and used to immunize mice. Mice receiving free CPG 7909 in a separate same site injection to the AMA1-C1/Alhydrogel had the same antibody responses as mice receiving AMA1-C1/Alhydrogel alone. For mice immunized with CPG 7909 bound to the AMA1-C1/Alhydrogel formulation, there was a bell shaped CPG 7909 dose response curve with the highest antibody response co-incident with the concentration of CPG 7909 that saturated binding to the Alhydrogel. At a higher CPG 7909 dose where 74% was unbound, there was no enhancement of response over AMA1-C1/Alhydrogel alone. Our results suggest that the adjuvant effects of CpGs are optimal when adsorbed to Alhydrogel and highlight the need for careful characterization of the vaccine formulation.
- Subjects :
- CpG Oligodeoxynucleotide
medicine.medical_treatment
Plasmodium falciparum
Dose-Response Relationship, Immunologic
Antibodies, Protozoan
Antigens, Protozoan
Enzyme-Linked Immunosorbent Assay
complex mixtures
Article
Mice
Immune system
Antigen
Malaria Vaccines
parasitic diseases
medicine
Animals
General Veterinary
General Immunology and Microbiology
biology
Public Health, Environmental and Occupational Health
biology.organism_classification
Molecular biology
Malaria
Infectious Diseases
Oligodeoxyribonucleotides
CpG site
Immunoglobulin G
Humoral immunity
Immunology
biology.protein
Molecular Medicine
Female
Antibody
Adjuvant
Subjects
Details
- ISSN :
- 0264410X
- Volume :
- 25
- Database :
- OpenAIRE
- Journal :
- Vaccine
- Accession number :
- edsair.doi.dedup.....1436044fb332b429fdfaed2f8777664b
- Full Text :
- https://doi.org/10.1016/j.vaccine.2007.05.007